Torii Pharmaceutical Co Ltd banner

Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 6 330 JPY Market Closed
Market Cap: ¥182.3B

Torii Pharmaceutical Co Ltd
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Torii Pharmaceutical Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Accrued Liabilities
¥466m
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
-4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Accrued Liabilities
¥93.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
182.3B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
3 547.66 JPY
Overvaluation 44%
Intrinsic Value
Price ¥6 330

See Also

What is Torii Pharmaceutical Co Ltd's Accrued Liabilities?
Accrued Liabilities
466m JPY

Based on the financial report for Jun 30, 2025, Torii Pharmaceutical Co Ltd's Accrued Liabilities amounts to 466m JPY.

What is Torii Pharmaceutical Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
-4%

Over the last year, the Accrued Liabilities growth was 8%. The average annual Accrued Liabilities growth rates for Torii Pharmaceutical Co Ltd have been 5% over the past three years , 3% over the past five years , and -4% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett